Patents by Inventor Lucia Mori

Lucia Mori has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240002465
    Abstract: Described herein is a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
    Type: Application
    Filed: July 17, 2023
    Publication date: January 4, 2024
    Applicant: UNIVERSITÄT BASEL
    Inventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
  • Patent number: 11702459
    Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: July 18, 2023
    Assignee: UNIVERSITÄT BASEL
    Inventors: Gennaro De Libero, Marco Lepore, Lucia Mori
  • Publication number: 20230099822
    Abstract: The invention relates to a method for modulating an interaction between an MR1 polypeptide and an MR1-specific T cell receptor molecule, whereby a MR1 polypeptide is contacted with a MR1 ligand compound that is a nucleobase adduct product reflecting a state of metabolic distress of a cell. The invention further relates to the use of compounds identified as MR1 ligands in vaccination or modulation of an MR1-restricted immune response.
    Type: Application
    Filed: January 18, 2021
    Publication date: March 30, 2023
    Applicant: UNIVERSITÄT BASEL
    Inventors: Gennaro DE LIBERO, Lucia MORI, Alessandro VACCHINI, Andrew CHANCELLOR, Julian SPAGNUOLO, Qinmei YANG
  • Publication number: 20220339271
    Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
    Type: Application
    Filed: September 11, 2019
    Publication date: October 27, 2022
    Applicant: Universität Basel
    Inventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
  • Publication number: 20190389926
    Abstract: The invention relates to a method of isolating a T cell that expresses a T cell receptor capable of binding specifically to an antigen presented by a cancer cell in association with an MR1 molecule. The method comprises the steps of (a) providing a preparation of T cells, (b) contacting the preparation with cancer cells expressing MR1 protein; (c) isolating a T cell that is specifically reactive to said cancer cells. The invention further relates to a method of preparing a T cell preparation expressing select MR1 recognizing T cell receptors from transgene expression vectors, the use of such T cell preparations in treatment of cancer, and to collections of MR1 reactive T cell receptor encoding nucleic acids and cells.
    Type: Application
    Filed: September 9, 2019
    Publication date: December 26, 2019
    Applicant: UNIVERSITÄT BASEL
    Inventors: Gennaro DE LIBERO, Marco LEPORE, Lucia MORI
  • Patent number: 8268801
    Abstract: The present invention relates to compounds of the following general formula (I) their process of preparation and their use in the treatment or the prophylaxis of tuberculosis.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: September 18, 2012
    Assignee: Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Germain Puzo, Jacques Prandi, Martine Gilleron, Gennaro De Libero, Julie Guiard, Lucia Mori, Samantha Paoletti
  • Publication number: 20100166801
    Abstract: The present invention relates to compounds of the following general formula (I) their process of preparation and their use in the treatment or the prophylaxis of tuberculosis.
    Type: Application
    Filed: January 11, 2008
    Publication date: July 1, 2010
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Germain Puzo, Jacques Prandi, Martine Gilleron, Gennaro De Libero, Julie Guiard, Lucia Mori, Samantha Paoletti